Novo Nordisk A/S NVO shares lost 2.7% on Friday after a surprising announcement regarding changes to its executive leadership ...

Lars Rebien Sørensen, who chairs the Novo Nordisk Foundation, will join its board as an observer while the company seeks a ...

Novo Nordisk is parting ways with its CEO Lars Fruergaard Jørgensen after the two parties mutually agreed that a change of ...

Novo Nordisk CEO Lars Fruergaard Jorgensen is stepping down per mutual agreement with the company. The company said Friday he ...

Jørgensen will step down after eight years as CEO, with a successor search underway while the company reaffirms confidence in ...

Novo Nordisk announced on Friday morning that its CEO Lars Fruergaard Jørgensen is stepping down after leading the company for eight years. In a release announcing the decision, the Danish pharma ...

Over Lars Fruergaard Jørgensen's eight years as CEO, Novo’s sales, profits and share price have almost tripled, the company ...

"The changes are made in light of the recent market challenges Novo Nordisk has been facing, and the development of the ...

Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing ...

Novo Nordisk A/S' CEO transition sparks governance concerns, but internal succession ensures stability. Click for my updated ...

As its obesity medication Wegovy loses a sizable portion of the market to Eli Lilly and Company (NYSE:LLY)’s competing ...

Investors may get a second bite at the apple, and a second chance to buy this GLP-1 drug leader at a discount price.